Lyophilized powder · Box of 10 vials · For research purposes only. Not for human consumption.
RESEARCH COMPOUND
MV2TZ
GLP-1/GIP Dual Agonist
MV2TZ is a synthetic peptide acting as a dual agonist at GLP-1 and GIP receptors. It is a subject of ongoing laboratory investigation within the incretin mimetic research class.
KEY RESEARCH AREAS
SELECT SIZE
SOLD BY THE BOX OF 10 VIALS
QUANTITY
BUY MORE, SAVE MORE
Add 1 more box to save 5%.
10mg x 10 vials · 10 vials per box
SECURE CHECKOUT — WE ACCEPT
- Visa
- Mastercard
- American Express
- Apple Pay
- Google Pay
For research purposes only · Not for human consumption
PUBLISHED RESEARCH
Research & Studies
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
PUBMED · 2021 · PMID 34186022
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
PUBMED · 2020 · PMID 32730231
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
PUBMED · 2018 · PMID 30473097
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
PUBMED · 2022 · PMID 35579691
Disclaimer. The publications above are independent third-party research hosted on PubMed and other public databases. They are provided for reference only. MedVita Wellness is not affiliated with the authors or publishers, does not endorse their conclusions, and makes no medical claims of any kind about this compound. Nothing here describes a use, benefit or outcome for any MedVita Wellness product. All products are sold strictly for laboratory and in vitro research use and are not for human or veterinary consumption.